National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$63.25
add to cart

Rights & Permissions

topleft topright

Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary (2005)
Board on Science, Technology, and Economic Policy (STEP)
National Cancer Policy Board (NCPB)

Citation Manager

. "Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema." Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary. Washington, DC: The National Academies Press, 2005.

Please select a format:

BibTeX EndNote RefMan


Page
74
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Economic Models of Colorectal Cancer Screening in Average-Risk Adults: Workshop Summary

SLIDE 2

SLIDE 2 NOTES: Elements of the Miscan Model’s structure are shown in this frame. The micro-simulation model treats time as a continuous variable, with discrete events occurring along the time line. So, for example, the appearance of a polyp of a particular size is a discrete event. (The model identifies three sizes.) But the dwelling time of such a polyp before it progresses to a larger size can be any length. Probability functions determine when the transition from one state to another will occur.

By parallel universe, we mean that the model first generates a complete simulated, or hypothetical, population of individuals with their complete natural history in the absence of screening. The results of that baseline simulation, with all pertinent clinical details, are stored. Then, the model begins again with the same population as before, but this time a particular screening strategy is imposed. Assumptions about the effect of screening on the clinical course of each patient determine a new set of simulated results. The net effect of the screening strategy is determined per life history by the changes that occur compared with the baseline.

The model provides outputs on a real population in any specific calendar year. Most of our published work has taken that approach. However, the model is flexible in that a specific cohort of individuals (such as 50 year old men) can be followed throughout the rest of their lives. For the pre-workshop exercise, we did adapt the model to a cohort structure.

Page
74
Front Matter (R1-R8)
Workshop Summary (1-30)
References (31-34)
Appendix A Workshop Agenda: Economic Models of Colorectal Cancer Screening in Average-Risk Adults (35-36)
Appendix B Workshop Participants (37-38)
Appendix C Workshop Speaker and Staff Biographies (39-44)
Appendix D Overview of Harvard Model--Karen M. Kuntz, ScD. (45-60)
Appendix E Description of the Laudabaum Colorectal Cancer Screening Model--Uri Ladabaum, M.D., M.S. (61-72)
Appendix F MISCAN-colon: An Overview--Marjolein van Ballegooijen, Iris Vogelaar, Rob Boer, Franka Loeve, Ann Zauber, Gerrit van Oortmar, and Dik Habbema (73-83)
Appendix G The Vanderbilt Colorectal Cancer Model--R.M. Ness, R.W. Klein, R.S. Dittus (84-104)
Appendix H Overview of the Vijan Colorectal Cancer Screening Model--Sandeep Vijan, M.D., M.S. (105-117)
Appendix I Cost-Effectiveness Analyses of Colorectal Cancer Screening: Results from a Pre-conference Modeling Exercise--Michael Pignone, M.D., (118-153)
Appendix J Recent Findings on Test Performance--Brian P. Mulhall, M.D., M.P.H. (154-188)
Appendix K Cost Issues in Cost Effectiveness Modeling of Colorectal Cancer Screening--Martin L. Brown, Ph.D. (189-207)
Appendix L Current Evidence on Compliance --Sally W. Vernon, M.A., Ph.D. (208-219)
Appendix M Recent Trends in Follow-up Surveillance in Medicare Beneficiaries--Todd Anderson, M.S. (220-231)
Appendix N Preliminary Results from CDC (232-240)
Appendix O Colorectal Cancer Surveillance Testing After Polypectomy--Deborah Schrag, M.D., M.P.H. (241-262)
Appendix P Natural History of Colorectal Adenomas and Cancer--T. R. Levin, M.D. (263-284)
Appendix Q CISNET—Cancer Intervention and Surveillance--Eric J. (Rocky) Feuer, Ph.D. (285-300)